$3.64
4.21% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
US0044682039
Symbol
ACHV
Sector
Industry

Achieve Life Sciences, Inc. Stock price

$3.64
-0.85 18.93% 1M
-1.00 21.55% 6M
-0.48 11.65% YTD
-0.47 11.44% 1Y
-4.51 55.34% 3Y
-7.06 65.98% 5Y
-4,770.36 99.92% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.16 4.21%
ISIN
US0044682039
Symbol
ACHV
Sector
Industry

Key metrics

Market capitalization $125.18m
Enterprise Value $92.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.99
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.27m
Free Cash Flow (TTM) Free Cash Flow $-24.95m
Cash position $42.91m
EPS (TTM) EPS $-1.13
P/E forward negative
Short interest 10.85%
Show more

Is Achieve Life Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Achieve Life Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Achieve Life Sciences, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Achieve Life Sciences, Inc. forecast:

Buy
100%

Financial data from Achieve Life Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.23 0.23
28% 28%
-
-0.23 -0.23
28% 28%
-
- Selling and Administrative Expenses 13 13
22% 22%
-
- Research and Development Expense 18 18
21% 21%
-
-31 -31
7% 7%
-
- Depreciation and Amortization 0.23 0.23
28% 28%
-
EBIT (Operating Income) EBIT -31 -31
7% 7%
-
Net Profit -33 -33
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Achieve Life Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Achieve Life Sciences, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will...
Neutral
GlobeNewsWire
26 days ago
Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping Cessation
Neutral
GlobeNewsWire
about one month ago
Coverage of pipeline drug profiles, including clinical and nonclinical stage products and therapeutics assessment by product type, stage, route of administration, and molecule type. Coverage of pipeline drug profiles, including clinical and nonclinical stage products and therapeutics assessment by product type, stage, route of administration, and molecule type.
More Achieve Life Sciences, Inc. News

Company Profile

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Head office United States
CEO Richard Stewart
Employees 22
Founded 1991
Website www.achievelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today